Background: Itching is a leading symptom of chronic hand eczema (CHE) having a great impact on patients. The determinants of itching in CHE are unclear. Objective: We performed a cross-sectional analysis investigating factors associated with the presence and severity of itch in CHE patients from the CARPE registry. Methods: We present baseline data on itch in relationship with sociodemographic factors, severity of CHE, atopy, contact allergy, treatment and patient- reported outcomes including health-related quality of life (HRQoL). Results: Of 1,051 patients with CHE, 78.1% reported itching. Significant positive associations with itching were observed for younger age groups (17-25 and 26-45 years), for moderate, severe and very severe CHE and for small/moderate impairment in HRQoL. Atopic skin diathesis, hardly being able to realize treatment recommendations and very or extremely large impairments in HRQoL were associated with itch severity. Conclusion: Taking the identified variables into account may help identify vulnerable groups most affected by (severe) itch.

Keywords:
Atopy, Chronic hand eczema, Dermatology Life Quality Index, Eczema, Itch, Pruritus, Quality of life, CARPE registry
1.
Diepgen TL, Andersen KE, Brandao FM, Bruze M, Bruynzeel DP, Frosch P, et al: Hand eczema classification: a cross-sectional, multicentre study of the aetiology and morphology of hand eczema. Br J Dermatol 2009;160:353-358.
2.
Coenraads PJ: Hand eczema. N Engl J Med 2012;367:1829-1837.
3.
Weisshaar E, Kallen U, Weiss M: ‘The itching hand' - important differential diagnoses and treatment. J Dtsch Dermatol Ges 2013;11:31-42.
4.
Weisshaar E, Apfelbacher C, Jager G, Zimmermann E, Bruckner T, Diepgen TL, et al: Pruritus as a leading symptom: clinical characteristics and quality of life in German and Ugandan patients. Br J Dermatol 2006;155:957-964.
5.
Weisshaar E, Dalgard F: Epidemiology of itch: adding to the burden of skin morbidity. Acta Derm Venereol 2009;89:339-350.
6.
Matterne U, Apfelbacher CJ, Vogelgsang L, Loerbroks A, Weisshaar E: Incidence and determinants of chronic pruritus: a population-based cohort study. Acta Derm Venereol 2013;93:532-537.
7.
Matterne U, Apfelbacher CJ, Loerbroks A, Schwarzer T, Buttner M, Ofenloch R, et al: Prevalence, correlates and characteristics of chronic pruritus: a population-based cross-sectional study. Acta Derm Venereol 2011;91:674-679.
8.
Halvorsen JA, Kupfer A, Dalgard F: The prevalence and intensity of itch among dermatological patients in 13 European countries. Acta Derm Venereol 2013;93:620-621.
9.
Apfelbacher CJ, Akst W, Molin S, Schmitt J, Bauer A, Weisshaar E, et al: CARPE: a registry project of the German Dermatological Society (DDG) for the characterization and care of chronic hand eczema. J Dtsch Dermatol Ges 2011;9:682-688.
10.
Apfelbacher C, Molin S, Weisshaar E, Bauer A, Elsner P, Mahler V, et al: Characteristics and provision of care in patients with chronic hand eczema: updated data from the CARPE registry. Acta Derm Venereol 2014;94:163-167.
11.
Coenraads PJ, Van Der Walle H, Thestrup-Pedersen K, Ruzicka T, Dreno B, De La Loge C, et al: Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis. Br J Dermatol 2005;152:296-301.
12.
Diepgen TL, Sauerbrei W, Fartasch M: Development and validation of diagnostic scores for atopic dermatitis incorporating criteria of data quality and practical usefulness. J Clin Epidemiol 1996;49:1031-1038.
13.
Hongbo Y, Thomas CL, Harrison MA, Salek MS, Finlay AY: Translating the science of quality of life into practice: what do dermatology life quality index scores mean? J Invest Dermatol 2005;125:659-664.
14.
Sommer F, Hensen P, Bockenholt B, Metze D, Luger TA, Stander S: Underlying diseases and co-factors in patients with severe chronic pruritus: a 3-year retrospective study. Acta Derm Venereol 2007;87:510-516.
15.
Dalgard F, Svensson A, Holm JO, Sundby J: Self-reported skin morbidity in Oslo. Associations with sociodemographic factors among adults in a cross-sectional study. Br J Dermatol 2004;151:452-457.
16.
Boehm D, Schmid-Ott G, Finkeldey F, John SM, Dwinger C, Werfel T, et al: Anxiety, depression and impaired health-related quality of life in patients with occupational hand eczema. Contact Dermatitis 2012;67:184-192.
17.
Stander S, Stumpf A, Osada N, Wilp S, Chatzigeorgakidis E, Pfleiderer B: Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden. Br J Dermatol 2013;168:1273-1280.
18.
Verhoeven EW, Kraaimaat FW, van de Kerkhof PC, van Weel C, Duller P, van der Valk PG, et al: Prevalence of physical symptoms of itch, pain and fatigue in patients with skin diseases in general practice. Br J Dermatol 2007;156:1346-1349.
19.
Bilac C, Ermertcan AT, Bilac DB, Deveci A, Horasan GD: The relationship between symptoms and patient characteristics among psoriasis patients. Indian J Dermatol Venereol Leprol 2009;75:551.
20.
Ghodsi SZ, Chams-Davatchi C, Daneshpazhooh M, Valikhani M, Esmaili N: Quality of life and psychological status of patients with pemphigus vulgaris using Dermatology Life Quality Index and General Health Questionnaires. J Dermatol 2012;39:141-144.
21.
Reich A, Hrehorow E, Szepietowski JC: Pruritus is an important factor negatively influencing the well-being of psoriatic patients. Acta Derm Venereol 2010;90:257-263.
22.
El-Baalbaki G, Razykov I, Hudson M, Bassel M, Baron M, Thombs BD, et al: Association of pruritus with quality of life and disability in systemic sclerosis. Arthritis Care Res (Hoboken) 2010;62:1489-1495.
23.
Dalgard F, Kupfer J, Halvorsen JA: The burden of itch among dermatological patients in Europe. Acta Derm Venereol 2013;93:607-608.
24.
O'Neill JL, Chan YH, Rapp SR, Yosipovitch G: Differences in itch characteristics between psoriasis and atopic dermatitis patients: results of a web-based questionnaire. Acta Derm Venereol 2011;91:537-540.
25.
Zachariae R, Lei U, Haedersdal M, Zachariae C: Itch severity and quality of life in patients with pruritus: preliminary validity of a Danish adaptation of the itch severity scale. Acta Derm Venereol 2012;92:508-514.
26.
Mabuchi T, Yamaoka H, Kojima T, Ikoma N, Akasaka E, Ozawa A: Psoriasis affects patient's quality of life more seriously in female than in male in Japan. Tokai J Exp Clin Med 2012;37:84-88.
27.
Nyunt WW, Low WY, Ismail R, Sockalingam S, Min AK: Determinants of health-related quality of life in psoriasis patients in Malaysia. Asia Pac J Public Health 2013, Epub ahead of print.
28.
Niemeier V, Nippesen M, Kupfer J, Schill WB, Gieler U: Psychological factors associated with hand dermatoses: which subgroup needs additional psychological care? Br J Dermatol 2002;146:1031-1037.
29.
Reich A, Heisig M, Phan NQ, Taneda K, Takamori K, Takeuchi S, et al: Visual analogue scale: evaluation of the instrument for the assessment of pruritus. Acta Derm Venereol 2012;92:497-501.
30.
Phan NQ, Blome C, Fritz F, Gerss J, Reich A, Ebata T, et al: Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. Acta Derm Venereol 2012;92:502-507.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.